These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648 [TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia: 2013 update on risk-stratification and management. Estey EH Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416 [TBL] [Abstract][Full Text] [Related]
4. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H; N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602 [TBL] [Abstract][Full Text] [Related]
5. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G; Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637 [TBL] [Abstract][Full Text] [Related]
7. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612 [TBL] [Abstract][Full Text] [Related]
9. Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine. Visani G; Olivieri A; Malagola M; Brunori M; Piccaluga PP; Capelli D; Pomponio G; Martinelli G; Isidori A; Sparaventi G; Leoni P Leuk Lymphoma; 2006 Jun; 47(6):1091-102. PubMed ID: 16840201 [TBL] [Abstract][Full Text] [Related]
10. Current and emerging therapies for acute myeloid leukemia. Robak T; Wierzbowska A Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045 [TBL] [Abstract][Full Text] [Related]
11. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090 [TBL] [Abstract][Full Text] [Related]
12. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD; J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018 [TBL] [Abstract][Full Text] [Related]
13. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140 [TBL] [Abstract][Full Text] [Related]
14. [Acute Myeloid Leukemia - Update 2022]. Rausch C; Hiddemann W; von Bergwelt-Baildon M; Spiekermann K; Herold T Dtsch Med Wochenschr; 2022 Sep; 147(17):1108-1114. PubMed ID: 36030783 [TBL] [Abstract][Full Text] [Related]
15. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway. Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110 [TBL] [Abstract][Full Text] [Related]
16. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia. Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943 [TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Testa U; Lo-Coco F Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716 [TBL] [Abstract][Full Text] [Related]
18. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience]. Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239 [TBL] [Abstract][Full Text] [Related]
19. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia. Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862 [TBL] [Abstract][Full Text] [Related]
20. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study. Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P; Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]